Changes induced in mouse lipid metabolism by simultaneous impact of antisense oligonucleotide derivatives to <i>apoB</i>, <i>PCSK9</i>, and <i>apoCIII</i> mRNAs
Development of new drugs able to decrease the level of “bad” cholesterol, in particular, based on antisense oligonucleotide derivatives (ASOs), remains relevant for the patients with familial hypercholesterolemia and/or intolerant to statins. The goal of the work was to assess the changes in the lip...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Siberian Branch of the Russian Academy of Sciences, Federal Research Center Institute of Cytology and Genetics, The Vavilov Society of Geneticists and Breeders
2020-01-01
|
| Series: | Вавиловский журнал генетики и селекции |
| Subjects: | |
| Online Access: | https://vavilov.elpub.ru/jour/article/view/2399 |
| _version_ | 1797214042640613376 |
|---|---|
| author | S. I. Oshevski Y. I. Ragino E. V. Kashtanova Y. V. Polonskaya E. M. Stakhneva V. P. Nikolin N. A. Popova N. A. Kolchanov M. I. Voevoda |
| author_facet | S. I. Oshevski Y. I. Ragino E. V. Kashtanova Y. V. Polonskaya E. M. Stakhneva V. P. Nikolin N. A. Popova N. A. Kolchanov M. I. Voevoda |
| author_sort | S. I. Oshevski |
| collection | DOAJ |
| description | Development of new drugs able to decrease the level of “bad” cholesterol, in particular, based on antisense oligonucleotide derivatives (ASOs), remains relevant for the patients with familial hypercholesterolemia and/or intolerant to statins. The goal of the work was to assess the changes in the lipid metabolism caused by variants of joint impact of the ASOs targeted to the mRNAs of its key genes: apoB, PCSK9, and apoCIII. Female C57BL/6J mice; nuclease-protected 13- and 20-nucleotide ASOs, and standard protocols for quantification of lipoproteins (HDL CHL, non-HDL CHL, and total CHL) and ALT in the blood serum were used in the work. The following combinations of ASOs were four times injected to the mouse caudal vein: 1) ASO to apoB, 2) ASO to apoCIII, 3) ASO to apoB and ASO to PCSK9, 4) ASO to apoB, ASO to PCSK9, and ASO to apoCIII, 5) ASO to apoB (three doses), ASO to PCSK9, and ASO to apoCIII (two doses), 6) ASO to PCSK9 and (ASO to apoCIII – only in the fourth administration). Triple weekly administration of these ASO combinations resulted in a decrease in non-HDL CHL by 25, 16, 35, 47, 60, and 7 %, respectively, as compared with the control and 1.8-, 1.5-, 1.9-, 2.4-, 3.1, and 1.24-fold higher HDL CHL/ non-HDL CHL ratio. The subsequent ASO injection with concurrent switching to a high-fat diet after 1 week resulted in a decrease in the non-HDL CHL by 28, 2, 28, 70, 33, and 49 % for ASOs (1–6), respectively, as compared with the control; the HDL CHL/non-HDL CHL ratio was 1.5-, 1.1-, 2-, 3.7-, 1.9-, and 2-fold better. The ALT concentration for all ASO combinations remained within the norm for the control animals, demonstrating the absence of any hepatotoxic effect. The best efficiency of ASOs requires selection of concentrations for single ASOs and their combinations as well as of the order and timing of administration. Thus, a new antisense approach is proposed. |
| first_indexed | 2024-03-07T16:05:33Z |
| format | Article |
| id | doaj.art-dfce909fe63a4b08ad14f9a1cb367e93 |
| institution | Directory Open Access Journal |
| issn | 2500-3259 |
| language | English |
| last_indexed | 2024-04-24T11:07:53Z |
| publishDate | 2020-01-01 |
| publisher | Siberian Branch of the Russian Academy of Sciences, Federal Research Center Institute of Cytology and Genetics, The Vavilov Society of Geneticists and Breeders |
| record_format | Article |
| series | Вавиловский журнал генетики и селекции |
| spelling | doaj.art-dfce909fe63a4b08ad14f9a1cb367e932024-04-11T15:31:02ZengSiberian Branch of the Russian Academy of Sciences, Federal Research Center Institute of Cytology and Genetics, The Vavilov Society of Geneticists and BreedersВавиловский журнал генетики и селекции2500-32592020-01-012381020102510.18699/VJ19.5791007Changes induced in mouse lipid metabolism by simultaneous impact of antisense oligonucleotide derivatives to <i>apoB</i>, <i>PCSK9</i>, and <i>apoCIII</i> mRNAsS. I. Oshevski0Y. I. Ragino1E. V. Kashtanova2Y. V. Polonskaya3E. M. Stakhneva4V. P. Nikolin5N. A. Popova6N. A. Kolchanov7M. I. Voevoda8Institute of Cytology and Genetics, SB RASInstitute of Cytology and Genetics, SB RASInstitute of Cytology and Genetics, SB RASInstitute of Cytology and Genetics, SB RASInstitute of Cytology and Genetics, SB RASInstitute of Cytology and Genetics, SB RASInstitute of Cytology and Genetics, SB RAS; Novosibirsk State UniversityInstitute of Cytology and Genetics, SB RASInstitute of Cytology and Genetics, SB RAS; Novosibirsk State University; Federal Research Center of Fundamental and Translational MedicineDevelopment of new drugs able to decrease the level of “bad” cholesterol, in particular, based on antisense oligonucleotide derivatives (ASOs), remains relevant for the patients with familial hypercholesterolemia and/or intolerant to statins. The goal of the work was to assess the changes in the lipid metabolism caused by variants of joint impact of the ASOs targeted to the mRNAs of its key genes: apoB, PCSK9, and apoCIII. Female C57BL/6J mice; nuclease-protected 13- and 20-nucleotide ASOs, and standard protocols for quantification of lipoproteins (HDL CHL, non-HDL CHL, and total CHL) and ALT in the blood serum were used in the work. The following combinations of ASOs were four times injected to the mouse caudal vein: 1) ASO to apoB, 2) ASO to apoCIII, 3) ASO to apoB and ASO to PCSK9, 4) ASO to apoB, ASO to PCSK9, and ASO to apoCIII, 5) ASO to apoB (three doses), ASO to PCSK9, and ASO to apoCIII (two doses), 6) ASO to PCSK9 and (ASO to apoCIII – only in the fourth administration). Triple weekly administration of these ASO combinations resulted in a decrease in non-HDL CHL by 25, 16, 35, 47, 60, and 7 %, respectively, as compared with the control and 1.8-, 1.5-, 1.9-, 2.4-, 3.1, and 1.24-fold higher HDL CHL/ non-HDL CHL ratio. The subsequent ASO injection with concurrent switching to a high-fat diet after 1 week resulted in a decrease in the non-HDL CHL by 28, 2, 28, 70, 33, and 49 % for ASOs (1–6), respectively, as compared with the control; the HDL CHL/non-HDL CHL ratio was 1.5-, 1.1-, 2-, 3.7-, 1.9-, and 2-fold better. The ALT concentration for all ASO combinations remained within the norm for the control animals, demonstrating the absence of any hepatotoxic effect. The best efficiency of ASOs requires selection of concentrations for single ASOs and their combinations as well as of the order and timing of administration. Thus, a new antisense approach is proposed.https://vavilov.elpub.ru/jour/article/view/2399antisense oligonucleotide derivativeslipid metabolism regulation |
| spellingShingle | S. I. Oshevski Y. I. Ragino E. V. Kashtanova Y. V. Polonskaya E. M. Stakhneva V. P. Nikolin N. A. Popova N. A. Kolchanov M. I. Voevoda Changes induced in mouse lipid metabolism by simultaneous impact of antisense oligonucleotide derivatives to <i>apoB</i>, <i>PCSK9</i>, and <i>apoCIII</i> mRNAs Вавиловский журнал генетики и селекции antisense oligonucleotide derivatives lipid metabolism regulation |
| title | Changes induced in mouse lipid metabolism by simultaneous impact of antisense oligonucleotide derivatives to <i>apoB</i>, <i>PCSK9</i>, and <i>apoCIII</i> mRNAs |
| title_full | Changes induced in mouse lipid metabolism by simultaneous impact of antisense oligonucleotide derivatives to <i>apoB</i>, <i>PCSK9</i>, and <i>apoCIII</i> mRNAs |
| title_fullStr | Changes induced in mouse lipid metabolism by simultaneous impact of antisense oligonucleotide derivatives to <i>apoB</i>, <i>PCSK9</i>, and <i>apoCIII</i> mRNAs |
| title_full_unstemmed | Changes induced in mouse lipid metabolism by simultaneous impact of antisense oligonucleotide derivatives to <i>apoB</i>, <i>PCSK9</i>, and <i>apoCIII</i> mRNAs |
| title_short | Changes induced in mouse lipid metabolism by simultaneous impact of antisense oligonucleotide derivatives to <i>apoB</i>, <i>PCSK9</i>, and <i>apoCIII</i> mRNAs |
| title_sort | changes induced in mouse lipid metabolism by simultaneous impact of antisense oligonucleotide derivatives to i apob i i pcsk9 i and i apociii i mrnas |
| topic | antisense oligonucleotide derivatives lipid metabolism regulation |
| url | https://vavilov.elpub.ru/jour/article/view/2399 |
| work_keys_str_mv | AT sioshevski changesinducedinmouselipidmetabolismbysimultaneousimpactofantisenseoligonucleotidederivativestoiapobiipcsk9iandiapociiiimrnas AT yiragino changesinducedinmouselipidmetabolismbysimultaneousimpactofantisenseoligonucleotidederivativestoiapobiipcsk9iandiapociiiimrnas AT evkashtanova changesinducedinmouselipidmetabolismbysimultaneousimpactofantisenseoligonucleotidederivativestoiapobiipcsk9iandiapociiiimrnas AT yvpolonskaya changesinducedinmouselipidmetabolismbysimultaneousimpactofantisenseoligonucleotidederivativestoiapobiipcsk9iandiapociiiimrnas AT emstakhneva changesinducedinmouselipidmetabolismbysimultaneousimpactofantisenseoligonucleotidederivativestoiapobiipcsk9iandiapociiiimrnas AT vpnikolin changesinducedinmouselipidmetabolismbysimultaneousimpactofantisenseoligonucleotidederivativestoiapobiipcsk9iandiapociiiimrnas AT napopova changesinducedinmouselipidmetabolismbysimultaneousimpactofantisenseoligonucleotidederivativestoiapobiipcsk9iandiapociiiimrnas AT nakolchanov changesinducedinmouselipidmetabolismbysimultaneousimpactofantisenseoligonucleotidederivativestoiapobiipcsk9iandiapociiiimrnas AT mivoevoda changesinducedinmouselipidmetabolismbysimultaneousimpactofantisenseoligonucleotidederivativestoiapobiipcsk9iandiapociiiimrnas |